摘要
转移性前列腺癌行去势治疗(androgen-deprivation therapy,ADT)后将逐渐发展为去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)。神经内分泌前列腺癌(neuroendocrine prostate cancer,NEPC)是CRPC的极差预后亚型,多由前列腺癌细胞发生神经内分泌分化(neuroendocrine differentiation,NED)引起,放化疗效果较差,平均生存期不到1年,约占因CRPC患者死亡的25%,目前其分子机制研究较有限。进一步研究NEPC发生的分子机制将为NEPC治疗药物的开发与应用提供新的思路。
Patients with metastatic prostate cancer are typically managed with androgen deprivation therapy. Most patients initially respond to treatment, but many eventually develop castration-resistant prostate cancer. Neuroendocrine prostate cancer （NEPC） is a highly aggressive subtype of castration-resistant prostate cancer, which often results from neuroendocrine differentiation of prostate cancer cells. NEPC has a dismal outcome with an average survival of less than 1 year and exhibits less response to radiochemotherapy. At least25% of patients with lethal castration-resistant prostate cancer are predicted to eventually develop this type of highly-aggres-sive NEPC. However, research on the molecular mechanism of NEPC is limited; thus, further studies are needed to explore the develop -ment and application of anticancer drugs for NEPC.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2016年第2期86-88,共3页
Chinese Journal of Clinical Oncology
基金
国家自然科学青年科学基金项目(编号:81502218)资助~~
关键词
前列腺癌
去势治疗
神经内分泌分化
prostate cancer, androgen deprivation therapy, neuroendocrine differentiation
